Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More
5 minute read

AstraZeneca Announced Data Presented at ESMO Show Enhertu Reduced Risk of Disease Progression by 72% in Patients with HER2-Positive Metastatic Breast Cancer

By Charles Gross
Today, 8:30 PM
Enhertu reduced the risk of disease progression or death by 72% vs. trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer   Ground-breaking Phase III head-to-head DESTINY-Breast03 results featured at ESMO Presidential Symposium support Enhertu as the potential new standard of care in previously treated patients  

AZN

Read More
3 minute read

Mirati Therapeutics Announced Clinical Data with Investigational Adagrasib Showed Adagrasib Alone and With Cetuximab Demonstrated Significant Clinical Activity and Broad Disease Control in Patients with KRAS G12C-Mutated Colorectal Cancer; Data to be…

By Charles Gross
Today, 8:30 PM
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced results from a cohort of the Phase 1/2 KRYSTAL–1 study evaluating adagrasib at the 600mg BID dose as both monotherapy and in combination with cetuximab in patients with heavily pretreated colorectal cancer harboring a KRASG12C mutation.

MRTX